September / October 2023
Features
Three looks at how AI may change retinal practice
Artificial intelligence models have shown the potential to decrease disparities in diabetic eye care, personalize management for nAMD treatment and predict outcomes for CRVO.
Lessons from Protocol AA for UWF imaging in DR
How to use the DRCR Retina Network roadmap for ultra-widefield imaging to evaluate eyes with nonproliferative diabetic retinopathy.
ILM peeling sans forceps: Is it time to make the switch?
Internal limiting membrane peeling with forceps is the gold standard, but cutter-based methods are safe, effective and potentially more efficient.
Metformin’s potential impact on AMD prevention
Multiple observational studies have shown the potential of the antidiabetic drug in the management of age-related macular degeneration.
Departments
Clinical Trial Closeup
Transgene shows restorative properties in nAMD
4D-150 is an intravitreal dual transgene genetic medicine that expresses both aflibercept and an mRNAi sequence that inhibits intracellular expression of VEGF-C.
Conference Review
Trial updates in GA, MacTel type 2 and DME
Four ASRS abstracts look at ANX007, pegcetacoplan, encapsulated cell therapy and tarcocimab.
Editor's Page
Imaging Forum
The dark side of pentosan
The vision consequences of a long-discontinued treatment for interstitial cystitis.
News
Social Media Specialist
Pharma marketing and social media
Some thoughts on avoiding the pharmaceutical digital marketing group-think.
Surgical Pearl Video
How to do intraretinal artery tPA injection
A stepwise approach to intraretinal artery cannulation for injection of tissue plasminogen activator into the central retinal artery.
Uveitis Forum
Managing inflammatory CNVM in uveitis
Solving the diagnostic and treatment challenges of choroidal neovascular membrane in uveitis.
Current Issue
Continuing Medical Education
Additional Publications
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Sponsored by Regeneron
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
Eyepoint Yutiq: A Discussion Among Experts on the Treatment of Uveitis Affecting the Posterior Segment
